Therapeutic potential of anti–interleukin‐17A aptamer: Suppression of interleukin‐17A signaling and attenuation of autoimmunity in two mouse models

Abstract

Our findings indicate that the chemically processed anti-IL-17A aptamer PEG21-2idT inhibits the actions of IL-17A as well as the development of autoimmunity in 2 mouse models of inflammation. These results offer for the first time an aptamer-based therapeutic approach to the treatment of Th17 cell-mediated autoimmune disorders.